NanoDx, SkyWater develop nanoscale tech for COVID testing

2021 10 06 20 31 5504 Nanotechnology 400

NanoDx and SkyWater are partnering to further develop and bring to market nanoscale sensor technology for rapid COVID-19, traumatic brain injury, sepsis, and stroke testing.

The nanosensor features wires that find and quantify biomarkers and infections in the blood; the technology is based on research that came out of Harvard University, according to NanoDx.

NanoDx and SkyWater plan to pursue an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) specifically for a two-minute, point-of-care COVID-19 test, NanoDx said.

Page 1 of 13
Next Page